BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

520 related articles for article (PubMed ID: 27209246)

  • 1. Germline BRCA1/2 mutation testing is indicated in every patient with epithelial ovarian cancer: A systematic review.
    Arts-de Jong M; de Bock GH; van Asperen CJ; Mourits MJ; de Hullu JA; Kets CM
    Eur J Cancer; 2016 Jul; 61():137-45. PubMed ID: 27209246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer.
    Eccleston A; Bentley A; Dyer M; Strydom A; Vereecken W; George A; Rahman N
    Value Health; 2017 Apr; 20(4):567-576. PubMed ID: 28407998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of germline BRCA1 and BRCA2 mutations in a multi-ethnic Asian cohort of ovarian cancer patients.
    Hasmad HN; Lai KN; Wen WX; Park DJ; Nguyen-Dumont T; Kang PCE; Thirthagiri E; Ma'som M; Lim BK; Southey M; Woo YL; Teo SH
    Gynecol Oncol; 2016 May; 141(2):318-322. PubMed ID: 26541979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer.
    Dann RB; DeLoia JA; Timms KM; Zorn KK; Potter J; Flake DD; Lanchbury JS; Krivak TC
    Gynecol Oncol; 2012 Jun; 125(3):677-82. PubMed ID: 22406760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil.
    Maistro S; Teixeira N; Encinas G; Katayama ML; Niewiadonski VD; Cabral LG; Ribeiro RM; Gaburo Junior N; de Gouvêa AC; Carraro DM; Sabino EC; Diz MD; Chammas R; de Bock GH; Folgueira MA
    BMC Cancer; 2016 Dec; 16(1):934. PubMed ID: 27914478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathological features of women with epithelial ovarian cancer and double heterozygosity for BRCA1 and BRCA2: A systematic review and case report analysis.
    Le Page C; Rahimi K; Rodrigues M; Heinzelmann-Schwarz V; Recio N; Tommasi S; Bataillon G; Portelance L; Golmard L; Meunier L; Tonin PN; Gotlieb W; Yasmeen A; Ray-Coquard I; Labidi-Galy SI; Provencher D; Mes-Masson AM
    Gynecol Oncol; 2020 Feb; 156(2):377-386. PubMed ID: 31753525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New paradigms for BRCA1/BRCA2 testing in women with ovarian cancer: results of the Genetic Testing in Epithelial Ovarian Cancer (GTEOC) study.
    Plaskocinska I; Shipman H; Drummond J; Thompson E; Buchanan V; Newcombe B; Hodgkin C; Barter E; Ridley P; Ng R; Miller S; Dann A; Licence V; Webb H; Tan LT; Daly M; Ayers S; Rufford B; Earl H; Parkinson C; Duncan T; Jimenez-Linan M; Sagoo GS; Abbs S; Hulbert-Williams N; Pharoah P; Crawford R; Brenton JD; Tischkowitz M
    J Med Genet; 2016 Oct; 53(10):655-61. PubMed ID: 27208206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Uptake of testing for germline
    Stearnes G; Nichols CB; Schofield L; O'Sullivan S; Pachter N; Cohen PA
    Int J Gynecol Cancer; 2019 Jul; 29(6):1038-1042. PubMed ID: 31101686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selecting Patients with Ovarian Cancer for Germline BRCA Mutation Testing: Findings from Guidelines and a Systematic Literature Review.
    Eccles DM; Balmaña J; Clune J; Ehlken B; Gohlke A; Hirst C; Potter D; Schroeder C; Tyczynski JE; Gomez Garcia EB
    Adv Ther; 2016 Feb; 33(2):129-50. PubMed ID: 26809252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRCA1 and BRCA2 mutations in ovarian cancer patients from China: ethnic-related mutations in BRCA1 associated with an increased risk of ovarian cancer.
    Shi T; Wang P; Xie C; Yin S; Shi D; Wei C; Tang W; Jiang R; Cheng X; Wei Q; Wang Q; Zang R
    Int J Cancer; 2017 May; 140(9):2051-2059. PubMed ID: 28176296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Young Israeli women with epithelial ovarian cancer: prevalence of BRCA mutations and clinical correlates.
    Helpman L; Zidan O; Friedman E; Kalfon S; Perri T; Ben-Baruch G; Korach J
    J Gynecol Oncol; 2017 Sep; 28(5):e61. PubMed ID: 28657222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRCA1/2 germline testing in non-mucinous epithelial ovarian carcinoma: changing international practice and implications for service provision.
    Coakley M; Cleary V; Power N; O'Reilly S
    Eur J Hum Genet; 2017 Feb; 25(2):167-168. PubMed ID: 27759028
    [No Abstract]   [Full Text] [Related]  

  • 13. A systematic review on the frequency of BRCA promoter methylation in breast and ovarian carcinomas of BRCA germline mutation carriers: Mutually exclusive, or not?
    Vos S; van Diest PJ; Moelans CB
    Crit Rev Oncol Hematol; 2018 Jul; 127():29-41. PubMed ID: 29891109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between family history, mutation locations, and prevalence of BRCA1 or 2 mutations in ovarian cancer patients.
    Singer CF; Tan YY; Muhr D; Rappaport C; Gschwantler-Kaulich D; Grimm C; Polterauer S; Pfeiler G; Berger A; Tea MM
    Cancer Med; 2019 Apr; 8(4):1875-1881. PubMed ID: 30821131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequency of germline BRCA1/2 mutations and association with clinicopathological characteristics in Turkish women with epithelial ovarian cancer.
    Sunar V; Korkmaz V; Topcu V; Cavdarli B; Arik Z; Ozdal B; Ustun YE
    Asia Pac J Clin Oncol; 2022 Feb; 18(1):84-92. PubMed ID: 33629534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive BRCA1 and BRCA2 mutational profile in Lithuania.
    Janavičius R; Rudaitis V; Mickys U; Elsakov P; Griškevičius L
    Cancer Genet; 2014 May; 207(5):195-205. PubMed ID: 25066507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients.
    Vergote I; Banerjee S; Gerdes AM; van Asperen C; Marth C; Vaz F; Ray-Coquard I; Stoppa-Lyonnet D; Gonzalez-Martin A; Sehouli J; Colombo N
    Eur J Cancer; 2016 Dec; 69():127-134. PubMed ID: 27821315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of germline BRCA1/2 mutations in women with tubo-ovarian high-grade serous carcinomas with and without serous tubal intra-epithelial carcinomas.
    Dowson CB; Stewart C; O'Sullivan S; Pachter N; Schofield L; Cohen PA
    Int J Gynecol Cancer; 2020 Jan; 30(1):94-99. PubMed ID: 31699802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention.
    Hanley GE; McAlpine JN; Miller D; Huntsman D; Schrader KA; Blake Gilks C; Mitchell G
    BMC Cancer; 2018 Mar; 18(1):254. PubMed ID: 29506471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The first Japanese nationwide multicenter study of
    Enomoto T; Aoki D; Hattori K; Jinushi M; Kigawa J; Takeshima N; Tsuda H; Watanabe Y; Yoshihara K; Sugiyama T
    Int J Gynecol Cancer; 2019 Jul; 29(6):1043-1049. PubMed ID: 31263023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.